Acadia Pharmaceuticals Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/2/2026)
| Balance Sheet | Total Assets | 1,564,190,000.00 | ROE | 78.47 % |
| Balance Sheet | Total Equity | 1,227,390,000.00 | ROA | 25.00 % |
| Cashflow | Capital Expenditures | -4,690,000.00 | P/FCF | 31.37 |
| Cashflow | Free Cash Flow | 105,146,000.00 | – | – |
| Cashflow | Operating Cash Flow | 109,836,000.00 | P/CF | 30.03 |
| Income | Earnings per Share (diluted) | 2.30 | Div. Yield | – |
| Income | Net Income | 391,000,000.00 | P/E | 8.37 |
| Income | Shares Outstanding | 171,359,000.00 | P/B | 2.69 |
| Income | Total Revenue | 1,071,510,000.00 | P/S | 3.08 |
Ratios calculated on: 10/14/2026
Company Description
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.acadia-pharm.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more